Literature DB >> 16185591

Sedation in clinical oncology.

Manuel González Barón1, César Gómez Raposo, Alvaro Pinto Marín.   

Abstract

The clinical status of terminal cancer patients is very complex and is affected by several severe symptoms, of extended duration, changing with time and of multifactorial origin. When there are no reasonable cancer treatments specifically able to modify the natural history of the disease, symptom control acquires priority and favours the possible better adaptation to the general inexorable deterioration related to the neoplasic progression. Despite the important advances in Palliative Medicine, symptoms are frequently observed that are intolerable for the patient and which do not respond to usual palliative measures. This situation, characterised by rapid deterioration of the patient, very often heralds, implicitly or explicitly, approaching death. The intolerable nature and being refractory to treatment indicates to the health-care team, on many occasions, the need for sedation of the patient. The requirement for sedation of the cancer patient is a situation that does not allow for an attitude of doubt regarding maintenance of the patient in unnecessary suffering for more than a reasonable time. Given the undoubted clinical difficulty in its indication, it is important to have explored at an earlier stage all usual treatments possible and the grade of response, commensurate with the patient's values and desires. Sedation consists of the deliberate administration of drugs in minimum doses and combinations required not only to reduce the consciousness of the patients but also to achieve adequate alleviation of one or more refractory symptoms, and with the prior consent given by the patient explicitly, or implicitly or delegated. Sedation is accepted as ethically warranted when considering the imperative of palliation and its administration and, whenever contemplated, the arguments that justify them are clear recorded in the clinical history. It is not an easy decision for the physician since, traditionally, the training has been "for the fight to save life". Nevertheless, it seems necessary to make some preparations regarding these problems that have a central affect on the clinical oncologist in his daily function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185591     DOI: 10.1007/bf02710268

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  Do hospice clinicians sedate patients intending to hasten death?

Authors:  T Morita; J Tsunoda; S Inoue; S Chihara
Journal:  J Palliat Care       Date:  1999       Impact factor: 2.250

2.  Communicating with surrogate decision-makers in end-of-life situations: substitutive descriptive language for the healthcare provider.

Authors:  Michael Limerick
Journal:  Am J Hosp Palliat Care       Date:  2002 Nov-Dec       Impact factor: 2.500

3.  Sedation, dehydration, and ethical uncertainty.

Authors:  Steven J Baumrucker
Journal:  Am J Hosp Palliat Care       Date:  2002 Sep-Oct       Impact factor: 2.500

4.  Drug-induced terminal sedation for symptom control.

Authors:  R E Enck
Journal:  Am J Hosp Palliat Care       Date:  1991 Sep-Oct       Impact factor: 2.500

5.  Slow euthanasia.

Authors:  J A Billings; S D Block
Journal:  J Palliat Care       Date:  1996       Impact factor: 2.250

6.  Morphine drips, terminal sedation, and slow euthanasia: definitions and facts, not anecdotes.

Authors:  B Mount
Journal:  J Palliat Care       Date:  1996       Impact factor: 2.250

7.  Sedation for delirium and other symptoms in terminally ill patients in Edmonton.

Authors:  R L Fainsinger; D De Moissac; I Mancini; D Oneschuk
Journal:  J Palliat Care       Date:  2000       Impact factor: 2.250

8.  Communicating prognosis to patients with metastatic disease: what do they really want to know?

Authors:  P N Butow; S Dowsett; R Hagerty; M H N Tattersall
Journal:  Support Care Cancer       Date:  2001-09-07       Impact factor: 3.603

9.  A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators.

Authors: 
Journal:  JAMA       Date:  1995 Nov 22-29       Impact factor: 56.272

10.  What do patients living with advanced cancer and their carers want to know? - a needs assessment.

Authors:  Rebecca K S Wong; Edmee Franssen; Ewa Szumacher; Ruth Connolly; Marty Evans; Beverley Page; Edward Chow; Charles Hayter; Tamara Harth; Lourdes Andersson; Joan Pope; Cyril Danjoux
Journal:  Support Care Cancer       Date:  2002-06-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.